May. 5 at 11:26 AM
$RVTY
🚨🚨🚨
Revenue of
$711 million; pro forma revenue of
$687 million; 7% revenue growth; 3% organic growth; 6% pro forma organic growth
GAAP EPS from continuing operations of
$0.37; adjusted EPS from continuing operations of
$1.06;
GAAP pro forma EPS from continuing operations of
$0.40; pro forma adjusted EPS from continuing operations of
$1.04
Announces intention to divest China Immunodiagnostics business
Updates full year 2026 guidance
